A Phase 2 interventional study of UT-15C in Pulmonary Hypertension, sponsored by United Therapeutics. Completed at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-05-27.
Sponsored by United Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing treprostinil in Hypertension, Pulmonary — 4 open to participants now, 4 under way, 1 of them phase 3. treprostinil · Hypertension, Pulmonary.
Among the 38 studies testing treprostinil in Hypertension, Pulmonary, this one is the 12th largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2010, is one of 7 in phase 2, and was the 15th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →4 of the 38 studies testing treprostinil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:
Valley Health System · Sites in United States
Ages 18+
Liquidia Technologies, Inc. · Sites in United States, Australia, Austria and 9 more countries
Ages 18–80
Magdi H. Yacoub · Sites in Egypt
Ages 18+
University of California, San Diego
Ages 18+
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 17 · Phase 4 9
First in 1998; this study’s year is marked. 2 started in 2010.
This study's enrollment of 50 is above the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 32 across the 37 interventional studies. Of the 29 that completed or were terminated, 19 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 38 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
36 studies in Hypertension, Pulmonary by United Therapeutics: 4 open now, 4 under way, 2 of them phase 3. Of 28 finished, 21 (75%) have results posted.
Among the 36 studies in Hypertension, Pulmonary by United Therapeutics, this one is the 14th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2010, is one of 5 in phase 2, and was the 16th registered.
United Therapeutics’s Hypertension, Pulmonary studies by the year they started, since 1998.
1 of the studies testing treprostinil in Hypertension, Pulmonary that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07116681University of California, San DiegoEffects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension | 2027-07-01 |
Add it to your calendar (.ics) → With an account.
Among the 38 studies testing treprostinil in Hypertension, Pulmonary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among United Therapeutics’s 36 in Hypertension, Pulmonary:
This tab as a report to print or save as PDF → With an account.
This is a prospective, randomized, parallel group study to assess the hemodynamic effect of three different dose regimens of a sustained release (SR) tablet of UT-15C in patients with exercise-induced pulmonary hypertension (PH), as measured by the change in peak total pulmonary resistance index (TPRI) during exercise from Baseline to Week 12.
Prospective, randomized, parallel group study with two periods: a 10 week, dose titration period, followed by a 2 week, dose maintenance period in patients with exercise-induced PH.
The study population will be randomized into Dose Group 1, Dose Group 2, or an Individual Maximum Tolerated Dose (iMTD) of UT-15C SR by Week 10 and maintained through Week 12. Patients may be either currently receiving an approved oral background therapy for their PH (phosphodiesterase-5 [PDE-5] inhibitor, OR endothelin receptor antagonist [ERA]) (no dual background therapy), or not currently receiving therapy for PH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A subject was eligible for inclusion in this study if all of the following criteria applied:
Had exercise-induced PH at Baseline (defined as a PAPm ≥ 30 mmHg during exercise).
Note: eligible subjects may or may not have had a PAPm ≥ 25 mmHg at rest
Exercise-induced PH may have been:
Had a Baseline pulmonary function tests as follows:
May or may not have been receiving an approved PDE-5 inhibitor OR an approved ERA.
Subjects receiving an approved ERA or an approved PDE-5 inhibitor must have been on a stable dose for 30 days prior to Baseline, and were willing to remain on a PDE-5 inhibitor or an ERA and at the same dose for the duration of the 12-week Treatment Phase. If a subject chose to discontinue their PDE-5 or ERA prior to entering this study, they must have had a ≥30 day between the last dose of the PDE-5 or ERA and start of the screening phase.
Exclusion Criteria-
A subject was not eligible for inclusion in this study if any of the following criteria applied:
Had PH associated with:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
UT-15C 0.25 mg twice daily
Drug: UT-15C
UT-15C 1.25 mg twice daily
Drug: UT-15C
UT-15C individual Maximum Tolerated Dose
Drug: UT-15C
oral
Also known as: treprostinil diethanolamine, sustained release
Change in Peak Total Pulmonary Resistance Index (TPRI) During Exercise From Baseline to Week 12
The effects of 12-week treatment with different doses of UT-15C on peak TPRI during exercise will be evaluated by comparing the change from Baseline to Week 12 at peak wattage on a pairwise basis between treatment groups. The primary measure of efficacy was the change from Baseline to Week 12 in peak TPRI during exercise assessed 3 to 6 hours after the subject's morning dose of UT-15C to obtain measurements at peak concentrations of treprostinil. The equation used to determine the Total Pulmonary Resistance Index (TPRI) (mmHg/\[L/min/m\^2\]) is Mean Pulmonary Artery Pressure (PAPm)/ Cardiac Index (CI).
Time frame: Baseline and Week 12
Change in Mean Pulmonary Artery Pressure (PAPm) From Baseline to Week 12
Pulmonary hypertension (PH) is an increase in pressure in the pulmonary vasculature defined as a mean pulmonary artery pressure (PAPm) greater than 25 mmHg at rest or greater than 30 mmHg with exercise, as measured by right heart catheterization. The PAPm values and their respective changes from Baseline to Week 12 at peak exercise will be summarized by treatment group and measured by Swan-Ganz right heart catheterization.
Time frame: Baseline and Week 12
Change in Cardiac Index (CI) From Baseline to Week 12
Cardiac Index (CI) relates the cardiac output (CO) from left ventricle to body surface area (BSA), thus relating heart performance to the size of the individual. The CI values and their respective changes from Baseline to Week 12 at peak exercise will be summarized by treatment group and measured by Swan-Ganz right heart catheterization.
Time frame: Baseline and Week 12
Change in 6-minute Walk Distance (6MWD) From Baseline to Week 12
The intent of the 6MWD test is to evaluate exercise capacity associated with carrying out activities of daily living. Change in 6MWD from Baseline to Week 12, correlates with the current clinical standard for assessing patient functional status in the treatment of PH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). Subjects were instructed to walk down a corridor at a comfortable speed as far as they could manage for six minutes. Distance \<500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation.
Time frame: Baseline and Week 12
Change in Borg Dyspnea Score (Following 6MWT) From Baseline to Week 12
The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea (difficulty in breathing) experienced during the six-minute walk test (6MWT). The Borg dyspnea score was assessed immediately following the 6MWT. Scores ranged from 0 (for no shortness of breath) to 10 (for the greatest shortness of breath ever experienced).
Time frame: Baseline and Week 12
Change in PH Symptoms From Baseline to Week 12
Symptoms of PH including fatigue, dyspnea, edema, dizziness, syncope, chest pain and orthopnea were assessed and severity grade values (i.e., 0, 1, 2 or 3) for each symptom were assigned for subjects. A severity of 0 indicated no symptoms, the maximum severity was 3, indicating severe symptoms. Median change in symptom severity from Baseline to Week 12 is described.
Time frame: Change from Baseline at 12 Weeks
Number of Participants With a Change From Baseline World Health Organization (WHO) Functional Classification at Week 12
The WHO Functional Class of pulmonary hypertension is a physical activity rating scale as follows: Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Class III: Marked limitation of physical activity. Class IV: Inability to carry out any physical activity without symptoms. Only participants who experienced a change in WHO functional classification from Baseline to Week 12 are described by class change below; all other participants maintained their Baseline WHO functional classification at Week 12.
Time frame: Change from Baseline at Week 12
Change in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) Concentrations From Baseline to Week 12
The N-terminal pro-BNP (NT-proBNP) serum concentration was assessed to compare the severity of heart failure at Baseline and Week 12.
Time frame: Baseline and Week 12
The recruitment period for this study was May 2010 to October 2012. Sites were located in the US only.
| Milestone | Dose Group 1 | Dose Group 2 | Dose Group 3 |
|---|---|---|---|
| Started | 11 | 19 | 20 |
| Completed | 10 | 18 | 18 |
| Not completed | 1 | 1 | 2 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
The effects of 12-week treatment with different doses of UT-15C on peak TPRI during exercise will be evaluated by comparing the change from Baseline to Week 12 at peak wattage on a pairwise basis between treatment groups. The primary measure of efficacy was the change from Baseline to Week 12 in peak TPRI during exercise assessed 3 to 6 hours after the subject's morning dose of UT-15C to obtain measurements at peak concentrations of treprostinil. The equation used to determine the Total Pulmonary Resistance Index (TPRI) (mmHg/\[L/min/m\^2\]) is Mean Pulmonary Artery Pressure (PAPm)/ Cardiac Index (CI).
| mmHg/(L/min/m^2) | Dose Group 1 | Dose Group 2 | Dose Group 3 |
|---|---|---|---|
| Baseline | 15.096 ± 11.668 | 13.954 ± 9.397 | 15.441 ± 10.013 |
| Week 12 | 14.608 ± 9.274 | 14.509 ± 9.463 | 13.423 ± 7.257 |
| Change from Baseline | -0.488 ± 7.132 | 0.555 ± 4.428 | -2.019 ± 5.332 |
Pulmonary hypertension (PH) is an increase in pressure in the pulmonary vasculature defined as a mean pulmonary artery pressure (PAPm) greater than 25 mmHg at rest or greater than 30 mmHg with exercise, as measured by right heart catheterization. The PAPm values and their respective changes from Baseline to Week 12 at peak exercise will be summarized by treatment group and measured by Swan-Ganz right heart catheterization.
| mmHg | Dose Group 1 | Dose Group 2 | Dose Group 3 |
|---|---|---|---|
| Baseline | 58.5 ± 20.7 | 49.1 ± 11.8 | 51.2 ± 17.5 |
| Week 12 | 58.5 ± 21.6 | 49.4 ± 13.4 | 50.8 ± 14.7 |
| Change from Baseline | 0.0 ± 6.0 | 0.3 ± 5.4 | -0.4 ± 6.7 |
Cardiac Index (CI) relates the cardiac output (CO) from left ventricle to body surface area (BSA), thus relating heart performance to the size of the individual. The CI values and their respective changes from Baseline to Week 12 at peak exercise will be summarized by treatment group and measured by Swan-Ganz right heart catheterization.
| L/min/m^2 | Dose Group 1 | Dose Group 2 | Dose Group 3 |
|---|---|---|---|
| Baseline | 5.337 ± 2.870 | 4.366 ± 1.462 | 3.940 ± 1.208 |
| Week 12 | 5.313 ± 3.352 | 4.188 ± 1.399 | 4.352 ± 1.372 |
| Change from Baseline | -0.024 ± 1.209 | -0.177 ± 0.716 | 0.412 ± 0.959 |
The intent of the 6MWD test is to evaluate exercise capacity associated with carrying out activities of daily living. Change in 6MWD from Baseline to Week 12, correlates with the current clinical standard for assessing patient functional status in the treatment of PH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). Subjects were instructed to walk down a corridor at a comfortable speed as far as they could manage for six minutes. Distance \<500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation.
| meters | Dose Group 1 | Dose Group 2 | Dose Group 3 |
|---|---|---|---|
| Baseline | 361.5 ± 82.4 | 338.0 ± 57.3 | 317.8 ± 55.2 |
| Week 12 | 407.6 ± 98.2 | 356.7 ± 89.8 | 349.5 ± 89.8 |
| Change from Baseline | 46.1 ± 74.9 | 18.7 ± 74.3 | 31.6 ± 64.9 |
The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea (difficulty in breathing) experienced during the six-minute walk test (6MWT). The Borg dyspnea score was assessed immediately following the 6MWT. Scores ranged from 0 (for no shortness of breath) to 10 (for the greatest shortness of breath ever experienced).
| score | Dose Group 1 | Dose Group 2 | Dose Group 3 |
|---|---|---|---|
| Baseline | 3.0 (1.0 to 5.0) | 3.8 (3.0 to 5.0) | 3.0 (2.0 to 6.0) |
| Week 12 | 2.5 (1.0 to 5.0) | 3.0 (2.0 to 6.0) | 3.0 (2.0 to 5.0) |
| Change from Baseline | 0.5 (-2.0 to 2.0) | 0.0 (-1.5 to 1.0) | 0.0 (-1.5 to 1.0) |
Symptoms of PH including fatigue, dyspnea, edema, dizziness, syncope, chest pain and orthopnea were assessed and severity grade values (i.e., 0, 1, 2 or 3) for each symptom were assigned for subjects. A severity of 0 indicated no symptoms, the maximum severity was 3, indicating severe symptoms. Median change in symptom severity from Baseline to Week 12 is described.
| units on a scale | Dose Group 1 | Dose Group 2 | Dose Group 3 |
|---|---|---|---|
| Change in Fatigue Symptoms from Baseline | 0.0 (-1.0 to 0.0) | 0.0 (-1.0 to 0.0) | 0.0 (-1.0 to 0.0) |
| Change in Dyspnea Symptoms from Baseline | -1.0 (-1.0 to 0.0) | 0.0 (-1.0 to 0.0) | -0.5 (-1.0 to 0.0) |
| Change in Edema Symptoms from Baseline | 0.0 (-1.0 to 0.0) | 0.0 (-1.0 to 1.0) | 0.0 (-1.0 to 0.0) |
| Change in Dizziness Symptoms from Baseline | 0.0 (-1.0 to 0.0) | 0.0 (-1.0 to 0.0) | 0.0 (-1.0 to 0.0) |
| Change in Syncope Symptoms from Baseline | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Change in Chest Pain Symptoms from Baseline | 0.0 (-1.0 to 0.0) | 0.0 (-1.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Change in Orthopnea Symptoms from Baseline | 0.0 (-1.0 to 0.0) | 0.0 (-1.0 to 0.0) | 0.0 (-1.0 to 0.0) |
The WHO Functional Class of pulmonary hypertension is a physical activity rating scale as follows: Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Class III: Marked limitation of physical activity. Class IV: Inability to carry out any physical activity without symptoms. Only participants who experienced a change in WHO functional classification from Baseline to Week 12 are described by class change below; all other participants maintained their Baseline WHO functional classification at Week 12.
| participants | Dose Group 1 | Dose Group 2 | Dose Group 3 |
|---|---|---|---|
| Change from Class II to Class III | 0 | 0 | 1 |
| Change from Class III to Class I | 1 | 0 | 0 |
| Change from Class III to Class II | 2 | 1 | 4 |
The N-terminal pro-BNP (NT-proBNP) serum concentration was assessed to compare the severity of heart failure at Baseline and Week 12.
| pg/mL | Dose Group 1 | Dose Group 2 | Dose Group 3 |
|---|---|---|---|
| Baseline | 678.7 ± 1530.0 | 565.4 ± 960.0 | 1092.1 ± 1768.9 |
| Week 12 | 654.4 ± 1133.7 | 750.5 ± 1223.3 | 1571.7 ± 2808.6 |
| Change from Baseline | -24.4 ± 592.1 | 185.1 ± 634.9 | 479.6 ± 2236.9 |
Collected over Adverse events were recorded throughout the 12 week study, including the screening phase, as well as 30 days post end of study visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Group 1 | — | 2/11 (18.2%) | 11/11 (100%) |
| Dose Group 2 | — | 0/19 (0%) | 17/19 (89.5%) |
| Dose Group 3 | — | 4/20 (20%) | 20/20 (100%) |
| Event | Dose Group 1 | Dose Group 2 | Dose Group 3 |
|---|---|---|---|
| ArrhythmiaCardiac disorders | 0/11 | 0/19 | 2/20 |
| HypervolaemiaMetabolism and nutrition disorders | 0/11 | 0/19 | 2/20 |
| HypokalaemiaMetabolism and nutrition disorders | 0/11 | 0/19 | 2/20 |
| Chest discomfortGeneral disorders | 1/11 | 0/19 | 0/20 |
| PneumoniaInfections and infestations | 1/11 | 0/19 | 0/20 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/11 | 0/19 | 0/20 |
| Haemorrhage intracranialNervous system disorders | 1/11 | 0/19 | 0/20 |
| Cardiac failureCardiac disorders | 0/11 | 0/19 | 1/20 |
| Right ventricular failureCardiac disorders | 0/11 | 0/19 | 1/20 |
| HyponatraemiaMetabolism and nutrition disorders | 0/11 | 0/19 | 1/20 |
| Event | Dose Group 1 | Dose Group 2 | Dose Group 3 |
|---|---|---|---|
| HeadacheNervous system disorders | 6/11 | 10/19 | 14/20 |
| NauseaGastrointestinal disorders | 2/11 | 8/19 | 13/20 |
| FlushingVascular disorders | 1/11 | 1/19 | 9/20 |
| DiarrhoeaGastrointestinal disorders | 1/11 | 7/19 | 8/20 |
| VomitingGastrointestinal disorders | 0/11 | 5/19 | 4/20 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/11 | 1/19 | 5/20 |
| FatigueGeneral disorders | 0/11 | 2/19 | 5/20 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/11 | 4/19 | 2/20 |
| Pain in jawMusculoskeletal and connective tissue disorders | 0/11 | 4/19 | 3/20 |
| AnthralgiaMusculoskeletal and connective tissue disorders | 1/11 | 2/19 | 4/20 |
| Age, Continuous(years) | Dose Group 1 | Dose Group 2 | Dose Group 3 | Total |
|---|---|---|---|---|
| Mean | 53.1 (22 to 74) | 58.9 (43 to 75) | 57.6 (32 to 72) | 57.1 (22 to 75) |
| Sex: Female, Male(Participants) | Dose Group 1 | Dose Group 2 | Dose Group 3 | Total |
|---|---|---|---|---|
| Female | 11 | 15 | 15 | 41 |
| Male | 0 | 4 | 5 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Dose Group 1 | Dose Group 2 | Dose Group 3 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 3 | 6 |
| Not Hispanic or Latino | 11 | 16 | 17 | 44 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Dose Group 1 | Dose Group 2 | Dose Group 3 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 1 | 3 |
| White | 10 | 18 | 19 | 47 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Dose Group 1 | Dose Group 2 | Dose Group 3 | Total |
|---|---|---|---|---|
| United States | 11 | 19 | 20 | 50 |
| PAH History(participants) | Dose Group 1 | Dose Group 2 | Dose Group 3 | Total |
|---|---|---|---|---|
| Idiopathic, heritable or drug or toxin-induced PAH | 5 | 6 | 6 | 17 |
| PAH associated with connective tissue diseases | 5 | 9 | 10 | 24 |
| PAH associated with HIV | 0 | 0 | 0 | 0 |
| PH associated with interstitial lung disease (ILD) | 0 | 4 | 3 | 7 |
| PH associated with sarcoidosis | 1 | 0 | 1 | 2 |
| Background PAH Therapy(participants) | Dose Group 1 | Dose Group 2 | Dose Group 3 | Total |
|---|---|---|---|---|
| Both PDE-5i and ERA Dual Therapy | 0 | 0 | 1 | 1 |
| ERA | 4 | 4 | 1 | 9 |
| PDE-5i | 3 | 6 | 7 | 16 |
| No Background Therapy | 4 | 9 | 11 | 24 |
| Baseline Six-Minute Walk Distance (6MWD)(meters) | Dose Group 1 | Dose Group 2 | Dose Group 3 | Total |
|---|---|---|---|---|
| Mean | 366.0 ± 79.6 | 338.1 ± 55.7 | 311.4 ± 67.4 | 333.6 ± 68.1 |
1 further baseline measures are reported on the registry.
The record gives a start of Apr 2010, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil